Market Place
Sourcing Support
Akebia Signs Supply Contract For Vafseo® Access In Dialysis
22 Oct 2024 //
PR NEWSWIRE
Akebia Announces Seven Poster Presentations at ASN Kidney Week 2024
15 Oct 2024 //
PR NEWSWIRE
CMS Grants TDAPA Reimbursement For Vafseo From January 2025
10 Oct 2024 //
PR NEWSWIRE
Akebia And U.S. Renal Care Sign Supply Contract For Vafseo
07 Oct 2024 //
PR NEWSWIRE
Akebia Therapeutics and U.S. Renal Care Initiate VOICE Trial of Vafseo®
05 Sep 2024 //
PR NEWSWIRE
Akebia Therapeutics to Present at Upcoming Investor Conferences
26 Aug 2024 //
PR NEWSWIRE
Akebia Therapeutics Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
PR NEWSWIRE
Akebia Therapeutics To Report Q2 2024 Results
02 Aug 2024 //
PR NEWSWIRE
Akebia unveils IRA-driven high price for Vafseo
12 Jul 2024 //
FIERCE PHARMA
Akebia Updates On Momentum Of Vafseo® (Vadadustat) Commercial Launch
11 Jul 2024 //
PR NEWSWIRE
Akebia Therapeutics To Present At H.C. Wainwright 3rd Annual Kidney Conference
27 Jun 2024 //
PR NEWSWIRE
Akebia Therapeutics Appoints Erik Ostrowski As CFO And Chief Business Officer
24 Jun 2024 //
PR NEWSWIRE
Akebia Reports Nasdaq Employee Inducement Grants
03 Jun 2024 //
PR NEWSWIRE
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference
23 May 2024 //
PR NEWSWIRE
Akebia Therapeutics Q1 2024 Financials, Business Highlights
09 May 2024 //
PR NEWSWIRE
Akebia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Apr 2024 //
PR NEWSWIRE
Vafseo® Approved by The U.S. Fda for The Treatment of Anemia
28 Mar 2024 //
PR NEWSWIRE
U.S. FDA approves Akebia`s anemia drug
28 Mar 2024 //
REUTERS
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets
27 Mar 2024 //
PR NEWSWIRE
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
PR NEWSWIRE
Akebia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2024 //
PR NEWSWIRE
Akebia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
PR NEWSWIRE
Akebia Announces Appointment of Nicholas Grund as Chief Commercial Officer
09 Jan 2024 //
PR NEWSWIRE
Akebia to Present at the 42nd Annual J.P. Morgan Healthcare Conference
20 Dec 2023 //
PR NEWSWIRE
Akebia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2023 //
PR NEWSWIRE
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
20 Nov 2023 //
PR NEWSWIRE
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
PR NEWSWIRE
Akebia Announces Modification of Loan Agreement with Pharmakon Advisors
02 Nov 2023 //
PR NEWSWIRE
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
18 Oct 2023 //
PR NEWSWIRE
Akebia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2023 //
PR NEWSWIRE
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
28 Sep 2023 //
PR NEWSWIRE
Akebia Announces Approval of Vafseo in Australia and Provides Commercial Update
26 Sep 2023 //
PR NEWSWIRE
Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference
06 Sep 2023 //
PR NEWSWIRE
Akebia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Sep 2023 //
PR NEWSWIRE
Akebia Therapeutics Reports Second Quarter 2023 Financial Results
25 Aug 2023 //
PR NEWSWIRE
After high-profile snub, Akebia plots vadadustat resubmission
24 Aug 2023 //
FIERCE PHARMA
Akebia to Report Second Quarter Financial Results by August 25, 2023
17 Aug 2023 //
PR NEWSWIRE
Akebia Therapeutics Provides Update on Form 10-Q Filing
10 Aug 2023 //
PR NEWSWIRE
Akebia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2023 //
PR NEWSWIRE
Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
19 Jul 2023 //
PR NEWSWIRE
Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023
18 Jul 2023 //
PR NEWSWIRE
Akebia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2023 //
PR NEWSWIRE
Akebia Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia
29 Jun 2023 //
PR NEWSWIRE
Akebia Announces Swissmedic Approval of Vafseo® (vadadustat)
20 Jun 2023 //
PR NEWSWIRE
Akebia Therapeutics to Present at Jefferies Healthcare Conference
02 Jun 2023 //
PR NEWSWIRE
Akebia`s Vafseo (Vadadustat) Receives Approval in the Europe
31 May 2023 //
EMA
Akebia to refile anemia drug vadadustat after FDA denied appeal
31 May 2023 //
ENDPTS
Akebia finds new partner for oral anemia drug in Europe
25 May 2023 //
FIERCE PHARMA
Akebia Enters into Agreement with Medice Arzneimittel Pütter GmbH&Co.KG
25 May 2023 //
PR NEWSWIRE
Krystal Biotech raises $160M via PIPE on heels of FDA approval for gene therapy
22 May 2023 //
ENDPTS
FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose
22 May 2023 //
PR NEWSWIRE
Akebia Announces UK MHRA Approval of Vafseo® (vadadustat)
22 May 2023 //
PR NEWSWIRE
Akebia Therapeutics to Report 1Q FYR and Discuss Recent Business Highlights
01 May 2023 //
PR NEWSWIRE
EU regulators clear Akebia`s renal anaemia therapy Vafseo
26 Apr 2023 //
PR NEWSWIRE
Akebia to Host Stockholder Information Session to Discuss Rationale
14 Apr 2023 //
PR NEWSWIRE
Akebia Announces Presentations at Kidney Foundation Spring Clinical Meetings
07 Apr 2023 //
PR NEWSWIRE
Akebia Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2023 //
PR NEWSWIRE
Akebia touts new data on anemia drug a year after rejection
04 Apr 2023 //
ENDPTS
Akebia Announces Positive Results from Vadadustat Alternative Dosing Study
03 Apr 2023 //
PR NEWSWIRE
Akebia proposes new dosing for oral anemia drug amid FDA dispute
03 Apr 2023 //
FIERCE PHARMA
